keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept placental growth factor

keyword
https://www.readbyqxmd.com/read/29077188/aflibercept-in-the-treatment-of-diabetic-macular-edema-a-review-and-consensus-paper
#1
Teresio Avitabile, Claudio Azzolini, Francesco Bandello, Francesco Boscia, Sandro De Falco, Diego Fornasari, Paolo Lanzetta, Leonardo Mastropasqua, Edoardo Midena, Federico Ricci, Giovanni Staurenghi, Monica Varano
PURPOSE: To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review. METHODS: Two round tables, involving 12 Italian experts, were organized: in the first one, 6 pharmacologic and clinical questions were selected and analyzed by a systematic literature review, using a population, intervention, control, and outcomes framework; in the second one, the nominal group technique was used to discuss relevant evidence related to each question...
October 14, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28967076/aflibercept-in-the-management-of-acute-retinal-necrosis-syndrome-related-macular-edema
#2
Leticia Ortega-Evangelio, Javier Navarrete-Sanchis, Basil K Williams, Juan Miguel Tomás-Torrent
PURPOSE: Acute retinal necrosis (ARN) is a panuveitis syndrome that may lead to severe complications such as cystoid macular edema (CME). There is no consensus about the best treatment. We report one case of CME secondary to ARN managed with intravitreal aflibercept. CASE REPORT: A 41-year-old woman with a history of successfully treated varicella-zoster virus-associated ARN developed an epiretinal membrane (ERM) and underwent pars plana vitrectomy, ERM removal, inner limiting membrane peel, and lensectomy...
September 14, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28965804/neutralization-of-placental-growth-factor-as-a-novel-treatment-option-in-diabetic-retinopathy
#3
Tine Van Bergen, Tjing-Tjing Hu, Isabelle Etienne, Geert E Reyns, Lieve Moons, Jean H M Feyen
The current standard of care in clinical practice for diabetic retinopathy (DR), anti-vascular endothelial growth factor (VEGF) therapy, has shown a significant improvement in visual acuity. However, treatment response can be variable and might be associated with potential side effects. This study was designed to investigate inhibition of placental growth factor (PlGF) as a possible alternative therapy for DR. The effect of the anti-PlGF antibody (PL5D11D4) was preclinically evaluated in various animal models by investigating different DR hallmarks, including inflammation, neurodegeneration, vascular leakage and fibrosis...
September 28, 2017: Experimental Eye Research
https://www.readbyqxmd.com/read/28761750/european-medicines-agency-approval-summary-zaltrap-for-the-treatment-of-patients-with-oxaliplatin-resistant-metastatic-colorectal-cancer
#4
REVIEW
Stefan Cristian Stanel, Jan Sjöberg, Tomas Salmonson, Paolo Foggi, Mariapaola Caleno, Daniela Melchiorri, Iordanis Gravanis, Kyriaki Tzogani, Francesco Pignatti
On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing regimen. Aflibercept is a recombinant fusion protein which blocks the activation of vascular endothelial growth factor (VEGF) receptors and the proliferation of endothelial cells, acting as a soluble decoy receptor that binds to VEGF-A with higher affinity than its native receptors, as well as placental growth factor and VEGF-B...
2017: ESMO Open
https://www.readbyqxmd.com/read/28427067/intravitreal-aflibercept-in-diabetic-macular-edema-long-term-outcomes
#5
REVIEW
Ugo Introini, Giuseppe Casalino
For decades, macular laser photocoagulation has been the standard of care in the treatment of diabetic macular edema (DME). With the relatively recent advent of anti-vascular endothelial growth factor (VEGF) agents, DME treatment has entered a new era. VEGF is a well-known pro-angiogenic and pro-permeability factor involved in the pathogenesis of DME. VEGF blockade has proven remarkably effective at reducing DME and improving visual acuity (VA) in eyes with center involved DME causing VA loss in several randomized controlled trials (RCTs)...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28365905/aflibercept-a-review-in-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#6
REVIEW
Sheridan M Hoy
Aflibercept (Eylea(®)) is a fully human, recombinant fusion protein available in various countries worldwide, including those of the EU, as well as the USA, for intravitreal use in the treatment of macular oedema secondary to branch retinal vein occlusion (BRVO) in adults. Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor (VEGF)-A and placental growth factor (PIGF), preventing these angiogenic factors from binding to and activating their cognate receptors...
May 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28116649/phase-i-trial-of-aflibercept-vegf-trap-with-radiation-therapy-and-concomitant-and-adjuvant-temozolomide-in-patients-with-high-grade-gliomas
#7
Lakshmi Nayak, John de Groot, Jeffrey S Wefel, Timothy F Cloughesy, Frank Lieberman, Susan M Chang, Antonio Omuro, Jan Drappatz, Tracy T Batchelor, Lisa M DeAngelis, Mark R Gilbert, Kenneth D Aldape, Alfred W K Yung, Joy Fisher, Xiaobu Ye, Alice Chen, Stuart Grossman, Michael Prados, Patrick Y Wen
Anti-vascular endothelial growth factor (VEGF) therapy has shown promise in the treatment of high-grade gliomas (HGG). Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B and placental growth factor, depleting circulating levels of these growth factors. The Adult Brain Tumor Consortium conducted a phase I trial of aflibercept and temozolomide (TMZ) in patients with newly diagnosed HGG with 2 dose levels and a 3+3 design. Three arms using aflibercept were examined; with radiation and concomitant temozolomide; with adjuvant temozolomide using the 5/28 regimen; and with adjuvant temozolomide using the 21/28 day regimen...
March 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28002269/efficacy-of-intravitreal-aflibercept-in-macular-telangiectasia-type-1-is-linked-to-the-ocular-angiogenic-profile
#8
Laura Kowalczuk, Alexandre Matet, Ali Dirani, Alejandra Daruich, Aude Ambresin, Irmela Mantel, Richard F Spaide, Natacha Turck, Francine Behar-Cohen
PURPOSE: To evaluate intravitreal aflibercept in macular telangiectasia Type 1 (MacTel 1) patients and measure their ocular angiogenic profile. METHODS: Eight subjects with MacTel 1 refractory to bevacizumab, ranibizumab, or laser therapy and switched to aflibercept were included. Best-corrected visual acuity, central macular thickness, and cystic areas quantified on optical coherence tomography B-scans were assessed during 12 months. Perifoveal capillary densities were measured on optical coherence tomography angiography...
December 20, 2016: Retina
https://www.readbyqxmd.com/read/27886182/vitreous-levels-of-placental-growth-factor-correlate-with-activity-of-proliferative-diabetic-retinopathy-and-are-not-influenced-by-bevacizumab-treatment
#9
E Al Kahtani, Z Xu, S Al Rashaed, L Wu, A Mahale, J Tian, E B Abboud, N G Ghazi, I Kozak, V Gupta, J F Arevalo, E J Duh
PurposePlacental growth factor (PlGF) is a member of the VEGF family that plays an important role in experimental models of diabetic retinopathy and retinal neovascularization. We aimed to investigate whether vitreous levels of PlGF correlated with proliferative diabetic retinopathy (PDR) status, VEGF levels, and bevacizumab treatment. We also analysed PDR membranes to confirm the presence of the PlGF receptor, FLT1, in endothelial cells.MethodsThis was a case-control study: undiluted vitreous fluid samples were obtained from 28 active PDR patients without preoperative bevacizumab treatment, 21 active PDR patients with preoperative bevacizumab treatment, 18 inactive PDR patients, and 21 control patients...
April 2017: Eye
https://www.readbyqxmd.com/read/27556218/the-combination-of-plgf-inhibition-and-mmc-as-a-novel-anti-scarring-strategy-for-glaucoma-filtration-surgery
#10
Tine Van Bergen, Bart Jonckx, Lieve Moons, Jean H M Feyen, Ingeborg Stalmans
PURPOSE: The complementary effects of mitomycin-C (MMC) and anti-placental growth factor (PlGF) therapy were explored and compared to the combined administration of MMC and aflibercept. Additionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients. METHODS: In the trabeculectomy mouse model, intracameral injection(s) of the PlGF inhibitor (5D11D4) were compared to MMC or aflibercept and to the combination of both compounds...
August 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27435924/antiangiogenic-and-antitumor-activities-of-aflibercept-a-soluble-vegf-receptor-1-and-2-in-a-mouse-model-of-hepatocellular-carcinoma
#11
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF receptor-1 and -2. Here, we analyzed the mechanisms of the antitumor effects of aflibercept in mouse hepatoma models. METHODS: In in vitro studies, we determined the effects of aflibercept on human umbilical vein cell (HUVEC) proliferation and bone marrow (BM) cell differentiation to endothelial progenitor cells (EPCs)...
July 2016: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/27079208/response-to-anti-vegf-a-treatment-of-retinal-pigment-epithelial-cells-in-vitro
#12
COMPARATIVE STUDY
Alessandra Puddu, Roberta Sanguineti, Carlo Enrico Traverso, Giorgio L Viviani, Massimo Nicolò
PURPOSE: The neovascular or wet form of age-related macular degeneration is characterized by the growth of abnormal blood vessels in the retina stimulated by vascular endothelial growth factors (VEGF). In the last decade, several anti-VEGF drugs have been developed for treating neovascular diseases of the eyes. This study was conducted to compare the effects of 2 anti-VEGF-A drugs, ranibizumab and aflibercept, on the expression and secretion of VEGF family members in retinal pigment epithelial cells (RPE) in vitro...
August 4, 2016: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/26907516/aflibercept-for-the-treatment-of-diabetic-macular-edema
#13
REVIEW
Keegan A Harkins, Mary Haschke, Diana V Do
Diabetic macular edema (DME) is an accumulation of fluid in the central retina, secondary to vascular-leakage from diabetic vascular damage. DME and other ophthalmic sequela of diabetes are the leading cause of blindness in 20 to 74-year-olds. The development of VEGF-inhibitors (anti-VEGF) has revolutionized DME treatment improving the clinician's ability to remove excess fluid from the macula, improving visual-acuity. Aflibercept is an anti-VEGF agent made of a recombinant fusion protein (consisting of VEGF receptors 1 and 2 extracellular domains) fused with the Fc-portion of human-IgG1, which binds both VEGF isoforms A and B, and placental growth factor...
May 2016: Immunotherapy
https://www.readbyqxmd.com/read/26720459/bevacizumab-and-aflibercept-activate-platelets-via-fc%C3%AE-riia
#14
Yoko Nomura, Makoto Kaneko, Kanjiro Miyata, Yutaka Yatomi, Yasuo Yanagi
PURPOSE: To confirm the formation of a drug-growth factor complex and investigate the effects of three VEGF inhibitors in the activation of platelets. METHODS: Growth factors and individual drugs were mixed and incubated. Scattered light intensity was measured by dynamic light scattering (DLS) to monitor the formation of drug-growth factor complex. Blood samples were obtained from 16 subjects (5 AMD patients and 11 healthy volunteers). Platelets obtained from the platelet-rich fraction by centrifugation were washed and resuspended in HEPES/Tyrode buffer...
December 2015: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/26490656/fluorouracil-leucovorin-and-irinotecan-associated-with-aflibercept-can-induce-microscopic-colitis-in-metastatic-colorectal-cancer-patients
#15
François Ghiringhelli, Julie Vincent, Françoise Beltjens, Leila Bengrine, Sylvain Ladoire
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF). This molecule binds to all isoforms of VEGF-A as well as VEGF-B and placental growth factor, preventing them from activating their respective receptors. Aflibercept is used for the treatment of metastatic colorectal cancer (mCRC) in association with irinotecan. For reasons that remain to be elucidated, the addition of aflibercept to irinotecan-based chemotherapy increases the incidence of grade 3-4 diarrhea...
December 2015: Investigational New Drugs
https://www.readbyqxmd.com/read/26442858/treatment-of-exudative-age-related-macular-degeneration-focus-on-aflibercept
#16
REVIEW
Alfredo García-Layana, Marta S Figueroa, Javier Araiz, José M Ruiz-Moreno, Francisco Gómez-Ulla, Luis Arias-Barquet, Nicholas Reiter
A formulation of aflibercept for intravitreal injection (Eylea) is approved for the treatment of patients with exudative age-related macular degeneration (AMD). Aflibercept has a significantly higher affinity for Vascular endothelial growth factor (VEGF)-A compared with other monoclonal anti-VEGF antibodies. In addition to binding all VEGF-A isoforms, aflibercept also blocks other proangiogenic factors such as VEGF-B and placental growth factor. The VIEW 1 and 2 trials showed this drug achieves improved results in patients with exudative AMD similar to those obtained with monthly ranibizumab, using a bimonthly treatment regimen after a loading dose of three intravitreal injections, which translates to less use of healthcare resources...
October 2015: Drugs & Aging
https://www.readbyqxmd.com/read/26413794/clinical-outcome-after-switching-therapy-from-ranibizumab-and-or-bevacizumab-to-aflibercept-in-central-retinal-vein-occlusion
#17
Maximilian Pfau, Heidi Fassnacht-Riederle, Matthias D Becker, Nicole Graf, Stephan Michels
PURPOSE: After 48 months, unresolved macular edema secondary to central retinal vein occlusion (CRVO) is present in more than half of the patients treated with ranibizumab/bevacizumab. Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as VEGF-B and placental growth factor inhibitor, might improve the clinical outcome in patients with CRVO who respond insufficiently to ranibizumab/bevacizumab. METHODS: The presented study is a retrospective analysis of CRVO patients (n = 13) responding insufficiently to ranibizumab and/or bevacizumab (requiring treatment every 6 weeks or more frequently)...
2015: Ophthalmic Research
https://www.readbyqxmd.com/read/26369798/clinical-efficacy-and-mechanistic-evaluation-of-aflibercept-for-proliferative-diabetic-retinopathy-acronym-clarity-a-multicentre-phase-iib-randomised-active-controlled-clinical-trial
#18
RANDOMIZED CONTROLLED TRIAL
Sobha Sivaprasad, A Toby Prevost, James Bainbridge, Rhiannon Tudor Edwards, David Hopkins, Joanna Kelly, Phil Luthert, Caroline Murphy, Jayashree Ramu, Negin Sarafraz-Shekary, Joana Vasconcelos, Beverley White-Alao, Philip Hykin
INTRODUCTION: Proliferative diabetic retinopathy (PDR) is the main cause of severe visual loss in people with diabetes mellitus. The standard treatment for this condition is panretinal photocoagulation (PRP). This laser treatment is inherently destructive, with predictable adverse effects on visual function, and a safer alternative is required. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors can induce short-term regression of retinal neovascularisation...
September 14, 2015: BMJ Open
https://www.readbyqxmd.com/read/26224565/aflibercept-a-new-target-therapy-in-cancer-treatment-a-review
#19
REVIEW
Vincenzo Ricci, Monica Ronzoni, Teresa Fabozzi
Angiogenesis is the process through which new blood vessels are formed from pre-existing vessels and is essential for the growth of all solid tumors. Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis, which is crucial for tumor growth and metastasis. Its inhibition with antiangiogenic drugs is thought to improve delivery of chemotherapy through vascular normalization and disruption of tumor vasculature. Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR)1 and VEGFR2 extracellular domains that binds to VEGF-A, VEGF-B, placental growth factor (PlGF) 1 and 2...
December 2015: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26220913/aflibercept-a-review-in-metastatic-colorectal-cancer
#20
REVIEW
Yahiya Y Syed, Kate McKeage
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of VEGF-A as well as VEGF-B and placental growth factor, and, thus, prevents them from binding to and activating their cognate receptors. In the USA and EU, intravenously administered aflibercept in combination with an infusion of leucovorin, fluorouracil and irinotecan (FOLFIRI) is approved for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after treatment with an oxaliplatin-containing regimen...
August 2015: Drugs
keyword
keyword
102761
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"